Article in Journal of immunology (Baltimore, Md. : 1950), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 1 institution in 1 country.
Stephanie C de BarrosDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA 90095.ORCID 0000-0003-1168-069X
Batul T SuterwalaDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA 90095.ORCID 0000-0003-3576-7482
Chongbin HeDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA 90095.
Shundi GeDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA 90095.
Brent ChickDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA 90095.
Garrett K BlumbergDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA 90095.
Kenneth KimDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA 90095.ORCID 0000-0003-2309-4858
Sam KleinDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA 90095.
Yuhua ZhuDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA 90095.
Xiaoyan WangDepartment of General Internal Medicine and Health Services Research, University of California Los Angeles, Los Angeles, CA 90095.
David CaseroDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA 90095.ORCID 0000-0002-7347-3330
Gay M CrooksDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA 90095; gcrooks@mednet.ucla.edu.
University of California, Los Angeles · US
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCLA OLDER AMERICANS INDEPENDENCE CENTERP30AG028748 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REUBEN, DAVID B. · 2006 to 2017
$9.8M
Stem Cell Therapies for Primary Immune DeficiencyP01AI072686 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CROOKS, GAY M · 2009 to 2010
$2.6M
Discovery and manipulation of mesenchymal signals for thymic rejuvenationR01AG049753 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CROOKS, GAY M · 2016 to 2020
$2.0M
A novel thymic implant strategy to induce T cell reconstitution and immune tolerance for patients with complete DiGeorge SyndromeR21AI119927 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CROOKS, GAY M · 2015 to 2016
Neonatal life marks the apogee of murine thymic growth. Over the first few days after birth, growth slows and the murine thymus switches from fetal to adult morphology and function; little is known about the cues driving this dramatic transition. In this study, we show for the first time (to our knowledge) the critical role of vascular endothelial growth factor (VEGF) on thymic morphogenesis beyond its well-known role in angiogenesis. During a brief window a few days after birth, VEGF inhibition induced rapid and profound remodeling of the endothelial, mesenchymal and epithelial thymic stromal compartments, mimicking changes seen during early adult maturation. Rapid transcriptional changes were seen in each compartment after VEGF inhibition, including genes involved in migration, chemotaxis, and cell adhesion as well as induction of a proinflammatory and proadipogenic signature in endothelium, pericytes, and mesenchyme. Thymocyte numbers fell subsequent to the stromal changes. Expression patterns and functional blockade of the receptors VEGFR2 and NRP1 demonstrated that VEGF mediates its pleiotropic effects through distinct receptors on each microenvironmental compartment of the developing mouse thymus.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pleiotropic Roles of VEGF in the Microenvironment of the Developing Thymus. · full record | OpenQuestion